Editas Medicine (EDIT) Competitors $1.70 -0.08 (-4.24%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EDIT vs. LENZ, KURA, SANA, DNA, ORIC, MGTX, VERV, XERS, IMTX, and QUREShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include LENZ Therapeutics (LENZ), Kura Oncology (KURA), Sana Biotechnology (SANA), Ginkgo Bioworks (DNA), ORIC Pharmaceuticals (ORIC), MeiraGTx (MGTX), Verve Therapeutics (VERV), Xeris Biopharma (XERS), Immatics (IMTX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. LENZ Therapeutics Kura Oncology Sana Biotechnology Ginkgo Bioworks ORIC Pharmaceuticals MeiraGTx Verve Therapeutics Xeris Biopharma Immatics uniQure Editas Medicine (NASDAQ:EDIT) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability. Does the MarketBeat Community prefer EDIT or LENZ? Editas Medicine received 303 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31353.23% Underperform Votes27546.77% LENZ TherapeuticsOutperform Votes10100.00% Underperform VotesNo Votes Does the media prefer EDIT or LENZ? In the previous week, Editas Medicine and Editas Medicine both had 2 articles in the media. Editas Medicine's average media sentiment score of 0.63 beat LENZ Therapeutics' score of 0.62 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend EDIT or LENZ? Editas Medicine currently has a consensus price target of $6.83, suggesting a potential upside of 286.06%. LENZ Therapeutics has a consensus price target of $35.40, suggesting a potential upside of 64.35%. Given Editas Medicine's higher possible upside, analysts plainly believe Editas Medicine is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more volatility and risk, EDIT or LENZ? Editas Medicine has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Do insiders and institutionals have more ownership in EDIT or LENZ? 71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is EDIT or LENZ more profitable? LENZ Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. LENZ Therapeutics' return on equity of -58.48% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% LENZ Therapeutics N/A -58.48%-55.50% Which has stronger earnings & valuation, EDIT or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than Editas Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$61.76M2.37-$153.22M-$2.56-0.69LENZ TherapeuticsN/AN/A-$124.65MN/AN/A SummaryLENZ Therapeutics beats Editas Medicine on 8 of the 15 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.11M$3.08B$5.81B$8.39BDividend YieldN/A1.51%4.75%3.98%P/E Ratio-0.6928.6624.9519.24Price / Sales2.37403.91375.54110.22Price / CashN/A168.6838.0534.58Price / Book0.413.487.334.28Net Income-$153.22M-$71.55M$3.18B$247.04M7 Day Performance-11.94%-6.66%-4.42%-4.36%1 Month Performance39.37%-9.02%-6.07%-5.60%1 Year Performance-83.19%-22.49%11.42%3.38% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.4836 of 5 stars$1.70-4.2%$6.83+303.1%-83.2%$140.74M$61.76M-0.67230Upcoming EarningsNews CoveragePositive NewsGap UpLENZLENZ Therapeutics2.1507 of 5 stars$22.00-2.4%$35.40+60.9%N/A$605MN/A0.00110Upcoming EarningsNews CoverageKURAKura Oncology4.2304 of 5 stars$7.74-1.8%$27.13+250.7%-66.4%$602.28MN/A-3.28130Earnings ReportAnalyst RevisionSANASana Biotechnology2.904 of 5 stars$2.64-8.5%$14.25+440.8%-78.4%$587.87MN/A-1.88380Upcoming EarningsNews CoverageGap DownDNAGinkgo Bioworks0.6706 of 5 stars$9.97-4.7%$4.58-54.1%N/A$566.47M$251.46M-0.751,218Gap UpORICORIC Pharmaceuticals4.3896 of 5 stars$7.84+3.7%$18.71+138.7%-47.9%$556.85MN/A-4.3180MGTXMeiraGTx4.666 of 5 stars$7.07-1.4%$23.50+232.4%+1.1%$553.71M$13.93M-5.86300VERVVerve Therapeutics2.5147 of 5 stars$6.47-8.0%$25.75+298.2%-62.1%$547.33M$11.76M-2.63110Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageXERSXeris Biopharma3.9818 of 5 stars$3.61-4.1%$5.15+42.9%+16.0%$537.44M$187.36M-8.01290IMTXImmatics2.2801 of 5 stars$4.47-3.9%$16.67+272.9%-67.7%$533.52M$115.50M-6.77260Short Interest ↓QUREuniQure3.6448 of 5 stars$10.84-5.6%$40.00+268.9%+95.0%$529.50M$28.59M-2.19500Short Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies LENZ Therapeutics Competitors Kura Oncology Competitors Sana Biotechnology Competitors Ginkgo Bioworks Competitors ORIC Pharmaceuticals Competitors MeiraGTx Competitors Verve Therapeutics Competitors Xeris Biopharma Competitors Immatics Competitors uniQure Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDIT) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
